Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion A Study Interrupted

被引：16
|
作者：
Sharfstein, Joshua M. [1 ]
Psaty, Bruce M. [2 ,3 ,4 ,5 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[2] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[3] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[4] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[5] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2016年 / 315卷 / 10期
关键词：
CONFIDENTIALITY; TRIALS;
D O I：
10.1001/jama.2016.1461
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：984 / 986
页数：3
相关论文
共 50 条
  • [41] EVALUATION OF THE RISK OF OBSTRUCTIVE SLEEP APNEA HYPOPNEA SYNDROME: COMPARATIVE STUDY IN POPULATIONS WITH NO CARDIOVASCULAR RISK AND WITH HIGH CARDIOVASCULAR RISK
    Ouedraogo, Nafi
    Sourabie, Adama
    Sempore, Yves
    Tiendrebeogo, Arnaud
    Ouedraogo, Valentin
    Yameogo, Tene Marceline
    Kyelem, Carole
    ACTA PHYSIOLOGICA, 2023, 239
  • [42] Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study
    Monarrez-Espino, Joel
    Galanti, Maria Rosaria
    Hansson, Jenny
    Janszky, Imre
    Soderberg-Lofdal, Karin
    Moller, Jette
    NICOTINE & TOBACCO RESEARCH, 2018, 20 (05) : 606 - 613
  • [43] Naltrexone plus Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study
    Grilo, Carlos M.
    Lydecker, Janet A.
    Morgan, Peter T.
    Gueorguieva, Ralitza
    CLINICAL THERAPEUTICS, 2021, 43 (01) : 112 - 123
  • [44] Cardiovascular Risk Evaluation for Breast Cancer Survivors: A Pilot Study
    Schlam, Ilana
    Debnath, Dipanjan
    Gallagher, Christopher
    Dilawari, Asma A.
    Tiwari, Shruti R.
    Aschalew, Malate
    Guebre-Xabiher, Hiwot
    Malloy, Stacy
    Graves, Kristi
    Barac, Ana
    Chitalia, Ami
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Method-of-Use Study of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight in Individuals with Obesity
    Halseth, Amy
    Shan, Kevin
    Walsh, Brandon
    Gilder, Kye
    Fujioka, Ken
    OBESITY, 2017, 25 (02) : 338 - 345
  • [46] A Preliminary, Open-Label Study of Naltrexone and Bupropion Combination Therapy for Treating Binge Drinking in Human Subjects
    Walter, T. Jordan
    Navarro, Montserrat
    Thiele, Todd E.
    Pedersen, Cort
    Kampov-Polevoy, Alexey
    Garbutt, J. C.
    ALCOHOL AND ALCOHOLISM, 2020, 55 (01): : 56 - 62
  • [47] Sustained-release bupropion versus naltrexone in the treatment of pathological gambling a preliminary blind-rater study
    Dannon, PN
    Lowengrub, K
    Musin, E
    Gonopolski, Y
    Kotler, M
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (06) : 593 - 596
  • [48] Naltrexone plus Bupropion Combination Causes Significant Weight Loss: A 56-Week Phase 3 Study
    Wadden, Thomas
    Klein, Samuel
    Greenway, Frank L.
    Erickson, Janelle
    Kim, Dennis D.
    Dunayevich, Eduardo
    Pl-Sunyer, F. Xavier
    DIABETES, 2009, 58 : A10 - A10
  • [49] Pretransplant cardiovascular evaluation and posttransplant cardiovascular risk
    Young, James B.
    Neumayer, Hans-Hellmut
    Gordon, Robert D.
    KIDNEY INTERNATIONAL, 2010, 78 : S1 - S7
  • [50] Bupropion response on sleep quality in patients with depression: Implications for increased cardiovascular disease risk
    Schramm, Preetam J.
    Poland, Russell E.
    Rao, Uma
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (02) : 207 - 214
12345